LP
TGTX icon

LMR Partners’s TG Therapeutics TGTX Stock Holding History

LMR Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$178K – 1518
2024
Q2 		$178K Buy
+10,000
New +$160K ﹤0.01% 862
2023
Q1 		– Sell
-10,000
Closed -$118K – 1164
2022
Q4 		$118K Hold
10,000
– – ﹤0.01% 1032
2022
Q3 		$59K Buy
+10,000
New +$65.6K ﹤0.01% 1085
2014
Q4 		– Sell
-22,557
Closed -$241K – 465
2014
Q3 		$241K Buy
+22,557
New +$209K 0.02% 238

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's TGTX Position: Q3 2024 in Review

LMR Partners sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 10,000 shares — an estimated $178K sold.

LMR Partners first reported a position in TGTX in Q3 2014 and held it in 4 quarters. The position peaked at $241K in Q3 2014. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • LMR Partners reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • LMR Partners sold 10,000 TG Therapeutics shares in Q3 2024, an estimated $178K.
  • LMR Partners first reported a position in TG Therapeutics in Q3 2014 and held it in 4 quarters.
  • LMR Partners's TG Therapeutics position peaked at $241K in Q3 2014.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.